Gamco Investors INC. ET AL Has $15.01 Million Holdings in Perrigo Company plc $PRGO

Gamco Investors INC. ET AL grew its position in shares of Perrigo Company plc (NYSE:PRGO) by 29.7% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,397,866 shares of the company’s stock after acquiring an additional 320,081 shares during the quarter. Gamco Investors INC. ET AL’s holdings in Perrigo were worth $15,013,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently modified their holdings of the company. EverSource Wealth Advisors LLC lifted its holdings in shares of Perrigo by 116.0% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,888 shares of the company’s stock worth $26,000 after purchasing an additional 1,014 shares in the last quarter. Geneos Wealth Management Inc. increased its stake in Perrigo by 439.1% during the 1st quarter. Geneos Wealth Management Inc. now owns 965 shares of the company’s stock valued at $27,000 after purchasing an additional 786 shares in the last quarter. UMB Bank n.a. increased its stake in Perrigo by 161.5% during the 4th quarter. UMB Bank n.a. now owns 1,964 shares of the company’s stock valued at $27,000 after purchasing an additional 1,213 shares in the last quarter. Meeder Asset Management Inc. acquired a new position in Perrigo during the fourth quarter worth $28,000. Finally, CWM LLC lifted its stake in shares of Perrigo by 230.0% in the fourth quarter. CWM LLC now owns 2,191 shares of the company’s stock valued at $31,000 after buying an additional 1,527 shares in the last quarter. 95.91% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

PRGO has been the subject of a number of analyst reports. Weiss Ratings upgraded shares of Perrigo from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday. Zacks Research upgraded shares of Perrigo from a “strong sell” rating to a “hold” rating in a report on Monday, April 27th. One analyst has rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $19.33.

Perrigo Trading Down 0.2%

Shares of Perrigo stock opened at $10.08 on Friday. The stock has a fifty day simple moving average of $10.60 and a 200 day simple moving average of $11.79. Perrigo Company plc has a 12-month low of $9.23 and a 12-month high of $28.43. The company has a market capitalization of $1.39 billion, a P/E ratio of -0.77, a price-to-earnings-growth ratio of 1.20 and a beta of 0.51. The company has a current ratio of 2.72, a quick ratio of 1.59 and a debt-to-equity ratio of 1.45.

Perrigo (NYSE:PRGO) last released its quarterly earnings results on Wednesday, May 6th. The company reported $0.43 EPS for the quarter, beating analysts’ consensus estimates of $0.39 by $0.04. Perrigo had a positive return on equity of 9.96% and a negative net margin of 43.50%.The business had revenue of $841.80 million during the quarter, compared to analyst estimates of $1.04 billion. During the same period in the prior year, the firm posted $0.60 EPS. Perrigo’s quarterly revenue was down 7.2% compared to the same quarter last year. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS. On average, sell-side analysts anticipate that Perrigo Company plc will post 2.11 earnings per share for the current fiscal year.

Perrigo Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, June 16th. Stockholders of record on Friday, May 29th were issued a $0.29 dividend. The ex-dividend date was Friday, May 29th. This represents a $1.16 annualized dividend and a dividend yield of 11.5%. Perrigo’s dividend payout ratio is currently -8.85%.

About Perrigo

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.